PIR International's 2023 EU/UK biotech board remuneration and diversity study

We are delighted to announce the launch of PIR International’s 2023 EU/UK Biotech Board Remuneration and Diversity Study.

Last year we embarked on producing one of the first dedicated studies which was independent and sourced directly from biotech board members and c-suite executives across the EU and UK. In this year’s exercise we are splitting our focus in to separate board and c-suite studies to engage each cohort independently, allowing us to dive deeper and give our audience greater insights on board trends, behaviours and makeup whilst capturing important data on remuneration and diversity in parallel.

This year’s board study was greeted by a strong response, giving us the ability to create an insightful report thanks to participation from board profiles and industry commentators across the European and UK biotechnology sector. To access the report, register on our website (www.pir-intl.com). We hope you find the report insightful and compelling.

Steve Bates OBE, CEO of BIA, said: “The UK Bioindustry Association welcomes the continued focus on diversity, equity and inclusion across the innovative life sciences and biotech sector in the UK, as evidenced by this report. It's encouraging that the PIR International’s EU & UK Board Remuneration and Diversity findings indicate that the industry is moving, albeit slowly, in the right direction. As our own BIA's Diversity and Inclusion in UK Biotech report shows recognising the gaps is crucial because it helps our sector remain committed to addressing them and making meaningful change.

BIA is taking concrete steps to support member companies in advancing diversity and inclusion in their own organisations with initiatives like BIA’s Women in Biotech programme and a series of Diversity, Equity, and Inclusion (DEI) workshops. 

For the UK and European life sciences and biotech sector to thrive, we need to attract and nurture talented innovators from diverse backgrounds. This will take a sustained collaborative effort. By ensuring that diversity and inclusion remain priorities in the biotech and life sciences sector, the industry can continue to flourish and contribute positively to society and the global economy.”

On diversity, data shows that out of 183 boards that took part in the EU & UK Board Remuneration and Diversity report, 25% have female board members, which is slightly more than last year. Similarly, BIA’s survey of 30 biotech companies with over 1,200 employees, shows that at the executive or founder level women account for 31.5% of C-suite roles and 26% of CEOs.

68% of those Board members studied believe that there is a distinct imbalance in ethnic representation on Biotech boards in the EU/UK. Only 4% have board members with a racial and ethnic minority background. According to data from the BIA’s Diversity and Inclusion report, 19.6 of respondents identified as members of racial or ethnic minorities and less than 15% of those are C-suite. For chief executives, the figure is 11 per cent; none are women from Black or minority ethnic backgrounds.

 



More news and updates 

Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion

Grey Wolf Therapeutics closes oversubscribed $50 million Series B Financing Expansion, led by ICG Life Sciences, to accelerate and expand first-of-its-kind antigen modulation technology. This brings the total Series B funds raised to nearly $100 million.

Somnus Scientific announces partnership with Life Science Group and Creonate

Somnus Scientific has agreed a collaborative partnership with Life Science Group (LSG) and Creonate Manufacturing for the next phase of product development.

Coulter Partners DEI: Views from leadership series - Ankit Mahadevia

In the latest instalment of its Diversity, Equity & Inclusion Leadership series, Coulter Partners spoke to Ankit Mahadevia, MD, Founder and Chair of Spero Therapeutics, and author of 'Quiet Leader, Loud Results'.

Discovery Park: Asymchem secures former Pfizer Sandwich, UK, development

Asymchem will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe.

Ultra-concentrated, ultra-rapid acting insulin demonstrates superiority in Phase I clinical trial in Type 2 diabetics

AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI

DLRC achieves King’s Award for Enterprise in International Trade

DLRC Ltd has been honoured with the King’s Award for Enterprise, recognising its outstanding performance in international trade. This places DLRC among a select group of only 252 organisations in the UK to receive this prestigious award.

Brainomix achieves breakthrough with FDA clearance of e-Lung AI software

Established market leader in stroke AI imaging receives its first FDA clearance in the lung imaging space; with this expanded foundation of AI-driven healthcare solutions, the Oxford-based company remains committed to driving innovation and delivering impactful advancements in imaging biomarkers.

Brainomix announces new studies further validating the impact of Brainomix 360 Stroke platform

With these latest studies, the firmly established European market leader in stroke AI imaging adds to its growing body of evidence; the latest research reflects the company’s extensive academic collaborations and its growing Life Science partnerships.

Optibrium partners with FMC Corporation to transform agrochemical discovery

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.

New study shows Brainomix 360 AI transforms stroke treatment in England

The study represents the largest real-world evaluation of stroke artificial intelligence (AI) imaging, involving more than 80,000 patients at 26 sites over a 3-year period; the results showed Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, while also improving the speed of treatment by 49 minutes.

 

More within